Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219602 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
A Phase 3 study of Type 2 Diabetes (T2DM) and Lipidemia, sponsored by NewAmsterdam Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07219602: Recruiting Phase 3 study of Type 2 Diabetes (T2DM) and Lipidemia, sponsored by NewAmsterdam Pharma.
NCT07219602 is a Phase 3 study of Type 2 Diabetes (T2DM) and Lipidemia that is actively recruiting participants, run by NewAmsterdam Pharma. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219602, a Phase 3 study of Type 2 Diabetes (T2DM) and Lipidemia, is actively recruiting participants, sponsored by NewAmsterdam Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- DRUG Obicetrapib 10 mg
Study Locations (20)
Florida
- UF Health Jackson - Jacksonville
- East Coast Institute of Research LLC - Jacksonville
- East Coast Institute of Research LLC - Lake City
- Floridian Clinical Research - Miami Lakes
North Carolina
- Velocity Clinical Research - Durham
- Floridian Clinical Research - Greensboro
- Centricity Research dba Lucas Research - Morehead City
Texas
- Juno Research LLC - Medical Center - Houston
- Clinical Trials of Texas dba Flourish Research - San Antonio
Virginia
- Burke Internal Medicine - Burke
- Burke International Medicine DBA Manassas Clinical Research Center - Manassas
Arizona
- Clinical Research Institute of Arizona - Sun City West
California
- Scripps Health - Whittier Diabetes Institute - La Jolla
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC) - Louisville
Maryland
- MD Medical Research - Oxon Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
What NCT07219602 shows while recruiting
NCT07219602 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Type 2 Diabetes (T2DM) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07219602 names 20 study sites across 13 states, led by Florida, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07219602 about?
NCT07219602 is a clinical study titled "A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome". This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients...
What is the current status of trial NCT07219602?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-12-11. Estimated completion is 2028-06.
What conditions does trial NCT07219602 study?
This clinical trial studies the following conditions: Type 2 Diabetes (T2DM), Lipidemia, Metabolic Syndrome (MetS).
What interventions are being tested in trial NCT07219602?
The interventions under investigation include: Placebo (OTHER), obicetrapib 10 mg + ezetimibe 10 mg FDC daily (DRUG), Obicetrapib 10 mg (DRUG).
Who is sponsoring clinical trial NCT07219602?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219602 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219602's enrollment target sits among peer trials
300 1123rd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI